Abstract: Embodiments are directed to managing operations. If Operations events are provided, event clusters may be associated with one or more Operations events, such that the Operations events may be associated with the event clusters based on characteristics of the Operations events. Metrics including resolution metrics, root cause analysis, notes, and other remediation information may be associated with the event clusters. Then a modeling engine may be employed to train models based on the Operations events, the event clusters, and the resolution metrics, such that the trained model may be trained to correlate and predict the resolution metrics from real-time Operations events. If real-time Operations events may be provided, the trained models may be employed to predict the resolution metrics that are associated with the real-time Operations events. If model performance degrades beyond accuracy requirements, new observations may be added to the training set and the model re-trained.

Abstract: Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.

Abstract: Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.

Abstract: Embodiments relate to a method, apparatus and program product and for generating a natural language processing model for an information domain. The method derives a skeleton of a natural language lexicon from a source model and uses it to form a dictionary. It also applies a set of syntactical rules defining concepts and relationships to the dictionary and expands the skeleton of the natural language lexicon based on a plurality of reference documents from the information domain. Using the expanded skeleton of the natural language lexicon, it also provides a natural language processing model for the information domain.

Abstract: Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.

Abstract: Embodiments are directed to managing operations. If Operations events are provided, event clusters may be associated with one or more Operations events, such that the Operations events may be associated with the event clusters based on characteristics of the Operations events. Metrics including resolution metrics, root cause analysis, notes, and other remediation information may be associated with the event clusters. Then a modeling engine may be employed to train models based on the Operations events, the event clusters, and the resolution metrics, such that the trained model may be trained to correlate and predict the resolution metrics from real-time Operations events. If real-time Operations events may be provided, the trained models may be employed to predict the resolution metrics that are associated with the real-time Operations events. If model performance degrades beyond accuracy requirements, new observations may be added to the training set and the model re-trained.

Abstract: Provided herein are methods of treating an epidermal growth factor receptor (EGFR) extracellular domain (ECD) mutant cancer in a human patient by administering to the patient an oligoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody combination (e.g., MM-151, comprising a first monoclonal antibody (P1X), a second monoclonal antibody (P2X), and a third monoclonal antibody (P3X), wherein P1X, P2X and P3X are in a 2:2:1 molar ratio). In one embodiment, the cancer comprises at least one mutation in the extracellular domain of EGFR selected from the group consisting of EGFR R451C, S464L, K467T, G465R, G465E, I491M, and S492R.

Abstract: Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.

Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.

Abstract: Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.

Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.

Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.

Abstract: Provided are systems and methods for partitioning of segments in a consumer credit segmentation tree. Segments can be defined based on regression tree analysis.

Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.